Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04836429 · ClinicalTrials.gov registry record · Phase 1

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

A Phase 1 study, sponsored by Roswell Park Cancer Institute.

Terminated
Registry status
Phase 1
Development phase
5
Enrollment target

NCT04836429 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04836429, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.

TERMINATED
Registry status
Phase 1
Development phase
5 participants
Enrollment target

Study Summary

This phase I trial evaluates the side effects of intraoperative photodynamic therapy with porfimer sodium in enhancing the response to immunotherapy with an immune checkpoint inhibitor drug in patients with non-small cell lung cancer with pleural disease. Photodynamic therapy is a technique that that works by combining a photosensitizing agent (porfimer sodium in this trial) and an intense light source to kill tumor cells. Photodynamic therapy may decrease the patients' symptoms and improve their quality of life.

Interventions

  • PROCEDURE Video-Assisted Thoracic Surgery
  • DRUG Porfimer Sodium
  • DRUG Photodynamic Therapy
  • DEVICE Intraoperative PDT

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2022-03-10
Est. Completion 2025-01-03
Phase Phase 1

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT04836429

The ClinicalTrials.gov registry entry for NCT04836429 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Video-Assisted Thoracic Surgery is the first listed.

NCT04836429 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04836429 about?

NCT04836429 is a clinical study titled "Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease". This phase I trial evaluates the side effects of intraoperative photodynamic therapy with porfimer sodium in enhancing the response to immunotherapy with an immune checkpoint inhibitor drug in patients with non-small cell lung cancer with pleural disease. Photodynamic therapy is a technique that tha...

What is the current status of trial NCT04836429?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-03-10. Estimated completion is 2025-01-03.

What interventions are being tested in trial NCT04836429?

The interventions under investigation include: Video-Assisted Thoracic Surgery (PROCEDURE), Porfimer Sodium (DRUG), Photodynamic Therapy (DRUG), Intraoperative PDT (DEVICE).

Who is sponsoring clinical trial NCT04836429?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.